183549-95-3

Basic information

• Product Name: (9S)-7-[3,5-bis(trifluoromethyl)benzyl]-9-methyl-5-(4-methylphenyl)-8,9,10,11-tetrahydro-7H-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione
• CAS NO: 183549-95-3
• Molecular Formula: C₃₀H₂₅F₆N₃O₂
• Molecular Weight: 573.53
• Mol File: 183549-95-3.mol

Chemical Properties

• Boiling Point: 650.2°C at 760 mmHg
• Flash Point: 347°C
• Density: 1.41g/cm³
• Vapor Pressure: 8.64E-17mmHg at 25°C
• Refractive Index: 1.599
• CAS DataBase Reference: (9S)-7-[3,5-bis(trifluoromethyl)benzyl]-9-methyl-5-(4-methylphenyl)-8,9,10,11-tetrahydro-7H-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione(CAS DataBase Reference)
• NIST Chemistry Reference: (9S)-7-[3,5-bis(trifluoromethyl)benzyl]-9-methyl-5-(4-methylphenyl)-8,9,10,11-tetrahydro-7H-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione(183549-95-3)
• EPA Substance Registry System: (9S)-7-[3,5-bis(trifluoromethyl)benzyl]-9-methyl-5-(4-methylphenyl)-8,9,10,11-tetrahydro-7H-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione(183549-95-3)

Safety Data

• Hazardous Substances Data: 183549-95-3(Hazardous Substances Data)

Upstream product

• 116060-91-4 3-(4-methylbenzoyl)-2-pyridine carboxylic acid 
• 508210-05-7 3-p-toluoyl-pyridine-2-carbonyl chloride 
• 110171-23-8 (S)-3-Methyl-4-<(tetrahydropyranyl)oxy>butanenitrile 
• 508210-17-1 8-Oxo-5-p-tolyl-8H-pyrano[3,4-b]pyridine-6-carbonyl chloride 
• 183550-78-9 5-(4-methylphenyl)-8-oxo-8H-pyrano[3,4-b]pyridine-6-carboxylic acid 
• 183550-80-3 N-[3,5-bis(trifluoromethyl)benzyl]-5-(4-methylphenyl)-8-oxo-8H-pyrano[3,4-b]pyridine-6-carboxamide 
• 217099-10-0 7-[(R)-3-Methyl-4-(tetrahydro-pyran-2-yloxy)-butyl]-8-oxo-5-p-tolyl-7,8-dihydro-[1,7]naphthyridine-6-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide 
• 183551-55-5 (R)-4-amino-2-methyl-1-butanol tetrahydropyranyl ether 
• 183551-02-2 (R)-N-[3,5-bis(trifluoromethyl)benzyl]-7,8-dihydro-7-(4-hydroxy-3-methylbutyl)-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide 
• 217099-11-1 7-[(S)-3-Methyl-4-(tetrahydro-pyran-2-yloxy)-butyl]-8-oxo-5-p-tolyl-7,8-dihydro-[1,7]naphthyridine-6-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide 
• 183812-31-9 (S)-4-amino-2-methyl-1-butanol tetrahydropyranyl ether 
• 183551-04-4 (S)-N-[3,5-bis(trifluoromethyl)benzyl]-7,8-dihydro-7-(4-hydroxy-3-methylbutyl)-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide 
• 183550-77-8 diethyl 5,6-dihydro-5-hydroxy-5-(4-methylphenyl)-8-oxo-8H-pyrano[3,4-b]pyridine-6,6-dicarboxylate 
• 88557-55-5 (S)-3-cyano-2-methyl-1-propanol tetrahydropyranyl ether 

Relevant articles and documents

PREVENTIVES/REMEDIES FOR EMOTIONAL DISORDERS

An agent for the prophylaxis or treatment of an emotional disorder, which contains the NK-1 receptor antagonist having particular properties of (1) having no serotonin uptake inhibitory effect, (2) being capable of migrating into the hypothalamus, or (3) having an inhibitory effect on micturition reflex, an agent for the prophylaxis or treatment of depression accompanied by urinary frequency, urinary incontinence and/or irritable bowel syndrome, which contains an NK-1 receptor antagonist, an agent for the prophylaxis or treatment of a mood disorder of patients with urinary frequency and urinary incontinence, and a circadian rhythm controller for the hypothalamic endocrine system are provided.

COMBINATION DRUGS

A pharmaceutical agent containing an NK-1 receptor antagonist, an NK-2 receptor antagonist and/or an anti-cholinergic drug in combination is provided, which is useful as a prophylactic or therapeutic agent of urinary frequency, urinary incontinence, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, osteoarthritis, pain, cough, irritable bowel syndrome, emesis, depression, anxiety, manic depressive psychosis or schizophrenia. More particularly, a pharmaceutical agent is provided, which contains a compound represented by the formula (I), wherein M ring is a heterocyclic ring having -N=Ca and Rb are bonded to each other to form ring A, or the same or different and each is a hydrogen atom or a substituent for ring M; ring A and ring B are each a homocyclic or heterocyclic ring optionally having substituents and at least one of them is a heterocyclic ring optionally having substituents; ring C is a homocyclic or heterocyclic ring optionally having substituents; ring Z is an optionally substituted heterocyclic ring containing nitrogen; and n is an integer of 1 to 6, or a salt thereof or a prodrug thereof, and an NK-2 receptor antagonist and/or an anti-cholinergic drug in combination.

HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE

A compound represented by the formula: wherein ring M is a heterocyclic ring wherein--X=Yis one of--N=C,--CO--N or--CS--N; Ra and Rb are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, with the proviso that at least one of them is an optionally substituted heterocyclic ring; Ring C is an optionally substituted homocyclic or heterocyclic ring; Ring Z is an optionally substituted nitrogen-containing heterocyclic ring; and n is an integer from 1 to 6, or a salt thereof has a tachykinin receptor antagonistic activity in vitro, and is useful for preventing or treating depression, anxiety, manic-depressive illness or psychopathy.

Axially chiral 1,7-naphthyridine-6-carboxamide derivatives as orally active tachykinin NK1 receptor antagonists: Synthesis, antagonistic activity, and effects on bladder functions

Cyclic analogues of N-[3,5-bis(trifluoromethyl)benzyl]-7,8-dihydro-N,7- dimethyl-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide (1) having a 6-9-membered ring (6-9) were synthesized and evaluated for NK1 antagonistic activities. The 8

CYCLIC COMPOUNDS, THEIR PRODUCTION AND USE

Novel compounds of the following general formula or salts thereof. STR1 wherein Ring M is a heterocyclic ring having--N=C ,--CO--N or--CS--N as the partial structure--X . . . Y ; R. sup.a and R. sup.b are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, and at least one of them is optionally substituted heterocyclic ring; Rng C is optionally substituted homocyclic or heterocyclic ring; Rng Z is an optionally substituted ring; and n represents an integer of from 1 to 6, or a salt thereof, which has anexcellent tachykinin receptor antagonistic effect, and their production, and pharmaceutical compositions.

Enantioselective synthesis of an axially chiral 1,7-naphthyridine-6-carboxamide derivative having potent antagonist activity at the NK1 receptor

A new and highly potent NK1 antagonist, (aR,9R)-3 [(aR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4- methylphenyl)-7H-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione], was atropdiastereoselectively synthesized in